Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Leukapheresis for acute leukemia with hyperleukocytosis: Line complications, resource utilization, and early mortality outcomes

Elizabeth Pollard, Brigitte Jia, Jarrod Smith, Somedeb Ball, Ashwin Kishtagari, Sanjay Mohan, Kateryna Fedorov, Vivek Patel

Blood (2025) 146 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2025-5188

Published: 2025

Journal Articles

Oral decitabine-cedazuridine versus parenteral hypomethylating agents in treatment-Naïve TP53-mutated Myelodysplastic Syndromes

Parth Patel, Michael Canonico, Hayley Hawkins, Michael Zargari, Kathryn Kennedy, Katherine Walsh, Erica Mittlebeeler, Bradley Yelvington, Laura Lee, Emily F. Mason, Kateryna Fedorov, Ashwin Kishtagari, Sanjay Mohan, Michael Savona, Somedeb Ball

Blood (2025) 146 (Supplement 1): 7389.

https://doi.org/10.1182/blood-2025-7389

Published: 2025

Journal Articles

Addition of venetoclax to hypomethylating agent offers limited incremental benefit for patients with treatment-naïve TP53-mutated myelodysplastic syndromes

Michael Canonico, Parth Patel, Hayley Hawkins, Kateryna Fedorov, Katherine Walsh, Kathryn Kennedy, Erica Mittlebeeler, Sarah Profitt, Sanjay Mohan, Emily F. Mason, Ashwin Kishtagari, Michael Savona, Somedeb Ball

Blood (2025) 146 (Supplement 1): 7388.

https://doi.org/10.1182/blood-2025-7388

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Impact of RAS mutations on outcomes in newly diagnosed AML patients

Melanie Naranjo, Jamila Mammadova, Sarah Profitt, Bradley Yelvington, Callee Brooks, Kathryn Kennedy, Erica Mittlebeeler, Ashwin Kishtagari, Somedeb Ball, Sanjay Mohan, Michael Savona, Kateryna Fedorov

Blood (2025) 146 (Supplement 1): 7026.

https://doi.org/10.1182/blood-2025-7026

Published: 2025

Journal Articles

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 790.

https://doi.org/10.1182/blood-2025-790

Published: 2025

Journal Articles

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Blood (2025) 146 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2025-3795

Published: 2025

Journal Articles

Behind the blood-brain barrier: Contemporary screening practice patterns and trends of central nervous system involvement in acute myeloid leukemia treated with intensive regimens and hypomethylating agent/venetoclax

Jamila Mammadova, Melanie Naranjo, Sarah Profitt, Bradley Yelvington, Callee Brooks, Kian Rahbari, Kathryn Kennedy, Erica Mittlebeeler, Somedeb Ball, Michael Savona, Ashwin Kishtagari, Sanjay Mohan, Kateryna Fedorov

Blood (2025) 146 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2025-1621

Published: 2025

Journal Articles

High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen

Kateryna Fedorov, Kathryn Kennedy, Erica Mittlebeeler, Sarah Profitt, Bradley Yelvington, Callee Brooks, Ashwin Kishtagari, Sanjay Mohan, Michael Savona, Somedeb Ball

Blood (2025) 146 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2025-1666

Published: 2025

Journal Articles

Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients

Kateryna Fedorov, Somedeb Ball, James E Denney, Alexis R Froenlich, Ashwin Kishtagari, Sanjay Mohan, Michael R. Savona, Emily F. Mason

Blood (2024) 144 (Supplement 1): 1474.

https://doi.org/10.1182/blood-2024-194259

Published: 2024

Journal Articles

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

John O. Mascarenhas, Viola Maria Popov, Sanjay Mohan, Zübeyde Nur Özkurt, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Zhuying Huang, Hope Qamoos, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Maciej Kaźmierczak

Blood (2024) 144 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2024-201642

Published: 2024

Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Blood (2023) 142 (Supplement 1): 624.

https://doi.org/10.1182/blood-2023-179291

Published: 2023

Journal Articles

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Naimisha Marneni, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Eden Ayele Biltibo, Vivek Patel, Shakthi Bhaskar, Reena Jayani, Jill Gilbert, Jordan Berlin, Ashwin Kishtagari, Sanjay Mohan, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Adetola A. Kassim, Muhamed Baljevic

Blood (2023) 142 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2023-190749

Published: 2023

Journal Articles

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 3339.

https://doi.org/10.1182/blood-2023-186664

Published: 2023

Journal Articles

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Srinivas K. Tantravahi, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Josef T. Prchal, Xulong Wang, Kamal Chamoun, Christopher J Walker, Pietro Taverna, Haris Ali

Blood (2023) 142 (Supplement 1): 622.

https://doi.org/10.1182/blood-2023-180844

Published: 2023

Journal Articles

Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

Blood (2023) 142 (Supplement 1): 5594.

https://doi.org/10.1182/blood-2023-189808

Published: 2023

Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Stephen T. Oh, MD, Jason Gotlib, MD MS, Sanjay Mohan, MD MSCI, Haris Ali, MD, Ekatherine Asatiani, MD, Francis Seguy, Feng Zhou, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-134574

Published: 2020

Journal Articles

miRNA Predictors of Response to DNA Methyltransferase Inhibitors

Amma Bosompem, MS, Yan Guo, PhD, Sanjay Mohan, MD, Begum Erdogan, MA, Muhammad Raza, MD, C. Michael Jones, MD FACP, Elizabeth A. Griffiths, MD, Annette S. Kim, MD PhD

Blood (2014) 124 (21): 1913.

https://doi.org/10.1182/blood.V124.21.1913.1913

Published: 2014

Journal Articles

A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia

Sawa Ito, MD, John Barrett, MD, Bipin N. Savani, MD, Madan Jagasia, MBBS, MS, Eolia Brissot, Samantha Miner, Nancy F. Hensel, Fariba Chinian, M.S., Keyvan Keyvanfar, BS, Minoo Battiwalla, MD MS, Michael R Savona, MD, Sanjay Mohan, MD, Mattias Carlsten, MD PhD, Pawel Muranski, MD, Stephen A. Strickland, MD MSCI

Blood (2014) 124 (21): 1047.

https://doi.org/10.1182/blood.V124.21.1047.1047

Published: 2014

Journal Articles

Impact of Myocardial Infarction On Survival in Acute Myeloid Leukemia

Joshua Lukenbill, D.O., Paul Elson, Sanjay Mohan, MD, Ramon V. Tiu, MD, Yogen Saunthararajah, MD, Leslie Farhat, Cassandra Kendeigh, Anjali Advani, MD, Edward A. Copelan, MD, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, MD, PhD, Mikkael A. Sekeres, MD, MS

Blood (2012) 120 (21): 4321.

https://doi.org/10.1182/blood.V120.21.4321.4321

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Leukapheresis for acute leukemia with hyperleukocytosis: Line complications, resource utilization, and early mortality outcomes

Oral decitabine-cedazuridine versus parenteral hypomethylating agents in treatment-Naïve TP53-mutated Myelodysplastic Syndromes

Addition of venetoclax to hypomethylating agent offers limited incremental benefit for patients with treatment-naïve TP53-mutated myelodysplastic syndromes

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Impact of RAS mutations on outcomes in newly diagnosed AML patients

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Behind the blood-brain barrier: Contemporary screening practice patterns and trends of central nervous system involvement in acute myeloid leukemia treated with intensive regimens and hypomethylating agent/venetoclax

High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen

Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

miRNA Predictors of Response to DNA Methyltransferase Inhibitors

A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia

Impact of Myocardial Infarction On Survival in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only